Review finds limited drug evidence and calls for stronger trials

Current perspectives in the pharmacological treatment of gambling disorder: psychedelics and beyond.

Expert opinion on pharmacotherapy • • Review • Relevant
🤖

AI Summary

This narrative review asks what pharmacological approaches may help treat gambling disorder (GD), a behavioral addiction, and assesses established and emerging options. It searched English-language literature published from January 2010 to January 2026. The review reports that opioid antagonists have the most consistent, though still limited, therapeutic signal, with possible benefits in selected patients who experience prominent gambling urges. Findings for antidepressants, mood stabilizers, antiepileptic drugs, and antipsychotics are mixed.

The review also discusses experimental approaches involving glutamatergic, noradrenergic, endocannabinoid, and orexin-related mechanisms, along with psychedelics and other neuroplasticity-oriented treatments such as psilocybin, ketamine/esketamine, and MDMA-assisted interventions. These approaches are described as promising, not established treatments. The authors call for adequately powered, controlled, and longitudinal trials and suggest research move toward treatment tailored to patient characteristics. As a narrative review, this abstract does not establish that any intervention is effective; it provides no quantitative trial results or sample sizes.

💡 Key Findings

1
Opioid antagonists have the most consistent, though still limited, therapeutic signal, with potential benefits in selected patients with prominent gambling urges.
High
90%
2
Evidence for antidepressants, mood stabilizers, antiepileptic drugs, and antipsychotics is heterogeneous.
High
90%
3
Endocannabinoid-related interventions are described as biologically plausible but largely experimental; the abstract does not report evidence establishing a clinical benefit.
High
90%
4
Psychedelic and neuroplasticity-oriented interventions are presented as promising research directions, but controlled, adequately powered, and longitudinal trials are needed before clinical implementation.
High
95%

📄 Original Abstract

INTRODUCTION: Gambling disorder (GD) is a heterogeneous behavioral addiction associated with dysregulated reward processing, impaired executive control, stress-system dysfunction, and maladaptive neuroplasticity. Despite its considerable clinical, social, and economic burden, no medication is currently approved specifically for GD, and available pharmacological strategies remain off label. AREAS COVERED: This narrative review examines established and emerging pharmacological approaches to GD. PubMed/MEDLINE, Scopus, and Web of Science were searched for English-language literature published between January 2010 and January 2026. Opioid antagonists show the most consistent, although still limited, therapeutic signal with potential benefits in selected patients with prominent gambling urges, whereas evidence for antidepressants, mood stabilizers, antiepileptic drugs, and antipsychotics remains heterogeneous. Glutamatergic, noradrenergic, endocannabinoid, and orexin-related interventions are biologically plausible but largely experimental. Psychedelic and neuroplasticity-oriented treatments, including psilocybin, ketamine/esketamine, and 3,4-Methylenedioxymethamphetamine (MDMA)-assisted interventions, may target cognitive inflexibility, compulsive behavior, and maladaptive reward learning. EXPERT OPINION: The available evidence supports a cautious, mechanism-informed approach to pharmacological research, while underscoring the need for adequately powered clinical trials and prospective evaluation of clinically relevant treatment-response indicators. Pharmacotherapy for GD should move toward phenotype-informed, multimodal treatment rather than a one-size-fits-all model. Emerging neuroplasticity-based interventions are promising, but adequately powered, controlled, and longitudinal trials are required before clinical implementation.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.